Edge Therapeutics
Edge Therapeutics, Inc. is a hospital-focused biopharmaceutical company established in 2009 and headquartered in New Providence, NJ. Edge has three products with six different applications that are all FDA-approved known ACTIVE agents with the proprietary microparticle formulation technology. Through the use of its proprietary, sustained release [...] delivery system, Edge aims to overcome the limitations of systemic [...] delivery by delivering drugs directly to the site of the injury without causing side effects in other parts of the body. Edge believes that this technology would PReVENT certain delayed complications, which would also significantly reduce unnecessary healthcare costs.
EG-1962 (nimodipine microparticles), Edge's lead product, is being developed to prevent secondary strokes after subarachnoid hemorrhage (SAH), which is caused by bleeding into the fluid around the brain. EG-1962 (nimodipine microparticles) combines a generic calcium channel blocker nimodipine, formulated in a biodegradable polymer carrier composed of FDA-approved materials. EG-1962 (nimodipine microparticles) is designed to be administered locally to the brain after surgery, directly to the site of the ruptured brain aneurysm or traumatic brain injury (TBI) to prevent vasospasm, a major Contributor to post-operative stroke. EG-1962 will be able to be Delivered in two different ways, either minimally invasively through an existing external ventricular drain (EVD) after the patient has Undergone endovascular coiling or implanting directly to the site of injury during surgical clipping. EG-1962 will be starting clinical trials in 2012.
EG-1964 is being developed to prevent recurrent chronic subdural hematoma (SDH). In 20-30% of patients, the treatment to drain the blood from the brain when a blood clot develops on the surface of the brain does not work. EG-1964 will help prevent the rebleeding to avoid another operation and various follow-up procedures which may cause complications or even death. EG-1964 would be administered to nearly all chronic SDH patients at the time of initial therapy.
EG-1960 is being developed to prevent the secondary complication of hematoma expansion (rebleeding) after a spontaneous intracerebral hemorrhage (ICH). Hematoma is the leading secondary cause of death and permanent disability following ICH. EG-1960 is expected to reduce hematoma expansion and prevent unwanted side effects outside of the brain.
In 2009 Edge was awarded a $500,000 grant from the New Jersey Commission on Science and Technology Edison Innovation Fund and in 2010 Edge received $100,000 in funding from the New Jersey Economic Development Authority.
Leadership Team
- President and Chief Executive Officer (CEO): Brian Leuthner
- Chief Scientific Officer (CSO): R. Loch Macdonald, MD, PhD
- Vice President, Regulatory & Quality: Priya Jambhekar, MS, RAC
- Chief Financial Officer: Bert Marchio
- Executive Vice President, Corporate Development: Carl Soranno, Esq.
- Associate Director, Corporate Operations: Som Ming Leung, PhD
Board of Directors
- Board Director, Chair of Compensation Committee: Sol Barer, PhD
- Board Director: Kurt Conti
- President & CEO, Co-founder, Board Chairman: Brian Leuthner
- Board Director, Chair of Audit Committee: James J. Loughlin
- CSO, Co-founder, Board Director: R. Loch Macdonald, MD, PhD
See also
- Nimodipine
- Subarachnoid hemorrhage
- Vasospasm
- Brain aneurysm
- Traumatic Brain Injury